Carbonari Dena M, Saine M Elle, Newcomb Craig W, Blak Betina, Roy Jason A, Haynes Kevin, Wood Jennifer, Gallagher Arlene M, Bhullar Harshvinder, Cardillo Serena, Hennessy Sean, Strom Brian L, Lo Re Vincent
Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Center for Pharmacoepidemiology Research and Training, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):999-1003. doi: 10.1002/pds.3844. Epub 2015 Jul 27.
Pharmacoepidemiology researchers often utilize data from two UK electronic medical record databases, the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN), and may choose to combine the two in an effort to increase sample size. To minimize duplication of data, previous studies examined the practice-level overlap between these databases. However, the proportion of overlapping patients remains unknown. We developed a method using demographic and pharmacy variables to identify patients included in both CPRD and THIN, and applied this method to measure the proportion of overlapping patients who initiated the oral anti-diabetic drug saxagliptin.
We conducted a cross-sectional study among patients initiating saxagliptin in CPRD and THIN between October 2009 and September 2012. Within both databases, we identified patients: (i) ≥18 years, (ii) newly prescribed saxagliptin, and (iii) with ≥180 days enrollment prior to saxagliptin initiation. Demographic data (birth year, sex, patient registration date, family number, and marital status) and prescriptions (including dates) for the first two oral anti-diabetic drugs prescribed within the study period were used to identify matching patients.
Among 4202 CPRD and 3641 THIN patients initiating saxagliptin, 2574 overlapping patients (61% of CPRD saxagliptin initiators; 71% of THIN saxagliptin initiators) were identified. Among these patients, 2474 patients (96%) perfectly matched on all demographic and prescription data.
Within each database, over 60% of patients initiating saxagliptin were included within both CPRD and THIN. Combined demographic and prescription data can be used to identify patients included in both CPRD and THIN.
药物流行病学研究人员经常利用来自英国两个电子病历数据库——临床实践研究数据链（CPRD）和健康改善网络（THIN）的数据，并且可能选择将两者合并以增加样本量。为了尽量减少数据重复，先前的研究考察了这些数据库之间实践层面的重叠情况。然而，重叠患者的比例仍然未知。我们开发了一种利用人口统计学和药学变量来识别同时纳入CPRD和THIN的患者的方法，并应用该方法来测量起始使用口服抗糖尿病药物沙格列汀的重叠患者的比例。
我们对2009年10月至2012年9月期间在CPRD和THIN中起始使用沙格列汀的患者进行了一项横断面研究。在两个数据库中，我们识别出：（i）年龄≥18岁；（ii）新开具沙格列汀处方；（iii）在起始使用沙格列汀之前登记≥180天的患者。研究期间开具的前两种口服抗糖尿病药物的人口统计学数据（出生年份、性别、患者注册日期、家庭编号和婚姻状况）和处方（包括日期）用于识别匹配患者。
在4202名CPRD和3641名起始使用沙格列汀的THIN患者中，识别出2574名重叠患者（占CPRD中起始使用沙格列汀患者的61%；占THIN中起始使用沙格列汀患者的71%）。在这些患者中，2474名患者（96%）在所有人口统计学和处方数据上完全匹配。
在每个数据库中，超过60%起始使用沙格列汀的患者同时纳入了CPRD和THIN。结合人口统计学和处方数据可用于识别同时纳入CPRD和THIN的患者。
